aberrations and in shape enough to tolerate FCR therapy, should still be good candidates for the latter, Using the reward being this treatment method could be completed in six months while ibrutinib has to be taken indefinitely.Some diploma of immunophenotype overlap among CLL, marginal zone lymphoma, and lymphoplasmacytic lymphoma exists. If the a